John Harling

Company: GlaxoSmithKline

Job title: Senior Scientific Director of Medicinal Chemistry

Bio:

I conducted both my B.Sc and Ph.D at Imperial followed by two years as a Postdoctoral Researcher at the University of Texas at Austin. Joined GlaxoSmithKline (then SmithKlineBeecham) as a Medicinal Chemist in 1991. During my >25 years at GSK I have worked in programs spanning Neurosciences, Cardiovascular and Respiratory therapeutic areas. In 2007 I was appointed as a Medicinal Chemistry Department Head in the Respiratory therapeutic area. In 2012 I became involved in the initiation of an exploratory effort to assess the potential of a new protein degradation technology through collaboration with Professor Craig Crews at Yale. My current position is Senior Scientific Director within Medicinal Chemistry at GSK where I have a remit to develop protein degradation capability at GSK.

Seminars:

Panel Discussion 1:50 pm

What are the similarities and differences between traditional drug discovery and TPD during the pre-clinical discovery efforts and clinical studies? Knowing what we know now, if you were to build a team and a strategy on TPD discovery and development from scratch, what changes would you make if any? What are the key translational bottlenecks…Read more

day: Day Two

Selecting Targets to Harness the Therapeutic Opportunities Afforded by PROTAC-Mediated Protein Degradation 2:00 pm

With a significant proportion of the intracellular proteome likely being amenable to PROTAC-mediated degradation, considerable focus needs to be placed on identifying the best therapeutic opportunities for this technology This presentation will share some experiences at GSK assessing different targets and the consideration of whether a PROTAC approach represented the modality of choice Data will…Read more

day: Day One